Pressmeddelanden från Faron Pharmaceuticals

Bevaka pressreleaser

Kurs från TradingView

Start Nyheter Pressreleaser Riktkurser Insynshandel Blankning Analyser Bloggar Videos Podcasts

Faron Pharmaceuticals

FARON PHARMACEUTICALS LTD: HOLDING(S) IN COMPANY 11 mar 19:20

Faron Pharmaceuticals

The Finnish Financial Supervisory Authority has approved Faron's rights offering prospectus 11 mar 09:00

Faron Pharmaceuticals

FARON PHARMACEUTICALS LTD: HOLDING(S) IN COMPANY 10 mar 08:48

Faron Pharmaceuticals

Inside Information: Faron publishes the terms and conditions of a fully covered rights offering of approximately EUR 40 million and updates cash runway 09 mar 18:45

Faron Pharmaceuticals

Update to Faron’s Financial Calendar and date of the Annual General Meeting in 2026 04 mar 17:45

Faron Pharmaceuticals

Correction: Faron Pharmaceuticals Ltd’s Annual Report 2025 published 04 mar 08:15

Faron Pharmaceuticals

Faron Pharmaceuticals Ltd’s Annual Report 2025 published 04 mar 08:00

Faron Pharmaceuticals

Faron’s Financial Statements Release 1 January to 31 December 2025 02 mar 11:00

Faron Pharmaceuticals

Faron Pharmaceuticals Ltd: Results of the Extraordinary General Meeting 02 mar 08:00

Faron Pharmaceuticals

Faron and City of Hope in process of developing a Phase II Investigator-Initiated Trial of Bexmarilimab in Relapsed/Refractory MDS 23 feb 08:00

Faron Pharmaceuticals

Faron’s Bexmarilimab Data Accepted for Poster Presentation at the BSH Annual Scientific Meeting 2026 19 feb 08:00

Faron Pharmaceuticals

Faron Announces Phase II BEAM-X IIT Led by the Nordic AML Group Evaluating Bexmarilimab in Post-Transplant AML 09 feb 18:45

Faron Pharmaceuticals

Faron Pharmaceuticals Ltd: NOTICE TO THE EXTRAORDINARY GENERAL MEETING 09 feb 18:35

Faron Pharmaceuticals

Inside Information: Faron Pharmaceuticals Ltd is planning a rights offering of approximately EUR 40 million to strengthen its capital structure and to drive lead asset bexmarilimab to key milestones 03 feb 17:00

Faron Pharmaceuticals

Faron Pharmaceuticals Ltd: Registration of New Shares 03 feb 08:00

Faron Pharmaceuticals

Faron Pharmaceuticals Ltd: Approval of Share Subscriptions Based on Special Rights in connection with Amortisation of the First and Second Tranche Bonds 29 jan 08:00

Faron Pharmaceuticals

New review published in Immunotherapy highlights the potential for Clever-1 inhibition with bexmarilimab to become the cornerstone of next-generation, multi-indication cancer immunotherapy 27 jan 08:00

Faron Pharmaceuticals

Faron Expands Bexmarilimab Program in Solid Tumors with a Randomized Phase I/II BEXAR IIT in Metastatic Soft-Tissue Sarcoma 13 jan 17:00

Faron Pharmaceuticals

Faron Pharmaceuticals Ltd: PDMR Dealing 08 jan 18:45

Faron Pharmaceuticals

Faron Pharmaceuticals Ltd: Approval of Share Subscriptions Based on Special Rights in connection with Advanced Amortisation of the First Tranche Bonds 22 dec 2025 08:00

Faron Pharmaceuticals

Faron announces strategic collaboration with The Institute for Cancer Research to launch BLAZE trial, targeting immunotherapy resistance in cancer 17 dec 2025 15:30

Faron Pharmaceuticals

Composition of Faron Pharmaceutical’s Shareholders’ Nomination Board 11 dec 2025 09:30

Faron Pharmaceuticals

Faron issues second tranche of bonds with an aggregated principal amount of EUR 10 million under its convertible bond arrangement 08 dec 2025 08:00

Faron Pharmaceuticals

Faron presents updated BEXMAB data at ASH 2025: Deep and durable responses in HR-MDS with favorable safety profile 04 dec 2025 17:00

Faron Pharmaceuticals

Faron Pharmaceuticals Ltd: Holding(s) in Company 03 dec 2025 11:00

Faron Pharmaceuticals

Faron Pharmaceuticals Ltd: Registration of New Shares 03 dec 2025 08:00

Faron Pharmaceuticals

Faron Pharmaceuticals Ltd: Approval of Share Subscriptions Based on Special Rights in connection with Amortisation of the First Tranche Bonds 02 dec 2025 08:00

Faron Pharmaceuticals

Faron Pharmaceuticals Ltd: Grant of Options 01 dec 2025 08:00

Faron Pharmaceuticals

Faron Pharmaceuticals Ltd: Appointment of CFO 27 nov 2025 08:00

Faron Pharmaceuticals

Faron’s Financial Calendar for 2026 24 nov 2025 18:15

Faron Pharmaceuticals

INSIDE INFORMATION: FARON INTENDS TO ISSUE SECOND TRANCHE OF BONDS WITH AN AGGREGATED PRINCIPAL AMOUNT OF EUR 10 MILLION UNDER ITS CONVERTIBLE BOND ARRANGEMENT 04 nov 2025 08:00

Faron Pharmaceuticals

Faron announces two bexmarilimab abstracts accepted at ASH 2025, including an oral presentation on treatment efficacy 03 nov 2025 08:00

Faron Pharmaceuticals

Faron hits key milestone with BEXMAB Phase 2 completion, advances to registrational trial with FDA alignment 28 okt 2025 08:00

Faron Pharmaceuticals

Faron Pharmaceuticals Ltd: Approval of Share Subscriptions Based on Special Rights in connection with Advanced Amortisation of the First Tranche Bonds 21 okt 2025 15:10

Faron Pharmaceuticals

FARON PHARMACEUTICALS LTD: HOLDING(S) IN COMPANY 20 okt 2025 08:00

Faron Pharmaceuticals

Updated BEXMAB Phase I/II Data presented at ESMO 2025 shows further improvement, strengthening the clinical profile of bexmarilimab in treatment-naïve HR-MDS patients 03 okt 2025 12:00

Faron Pharmaceuticals

Faron Pharmaceuticals Ltd: Registration of New Shares 03 okt 2025 08:00

Faron Pharmaceuticals

Faron Pharmaceuticals Ltd: Approval of Share Subscriptions Based on Special Rights in connection with Amortisation of the First Tranche Bonds 19 sep 2025 08:00

Faron Pharmaceuticals

Faron Pharmaceuticals Ltd: Exercise of Options, Director Dealing and Issue of Equity 12 sep 2025 17:25

Faron Pharmaceuticals

Correction: FARON PHARMACEUTICALS LTD: HALF-YEAR FINANCIAL RESULTS 1 JANUARY – 30 JUNE 2025 27 aug 2025 08:00

Faron Pharmaceuticals

FARON PHARMACEUTICALS LTD: HALF-YEAR FINANCIAL RESULTS 1 JANUARY – 30 JUNE 2025 19 aug 2025 08:00

Faron Pharmaceuticals

Faron Pharmaceuticals Ltd: Notice of Half-Year Financial Results 18 aug 2025 08:00

Faron Pharmaceuticals

Inside Information: Faron to advance bexmarilimab into a registrational Phase 2/3 study in treatment-naïve (frontline) HR-MDS after positive meeting with the FDA 08 aug 2025 16:00

Faron Pharmaceuticals

Faron Pharmaceuticals Ltd: Holding(s) in Company 08 aug 2025 09:30

Faron Pharmaceuticals

Faron announces extension to its key patent family around bexmarilimab and targeting Clever-1 in cancers with a new US patent granted 07 aug 2025 08:00

Faron Pharmaceuticals

Faron Pharmaceuticals Ltd: Approval of Share Subscriptions Based on Special Rights in connection with Advanced Amortisation of the First Tranche Bonds 06 aug 2025 08:00

Faron Pharmaceuticals

Inside Information: Faron to present updated BEXMAB data in frontline HR-MDS to FDA; complete remission rate substantially increased to 43%30 jul 2025 08:30

Faron Pharmaceuticals

FARON ANNOUNCES ACCEPTANCE OF BEXMARILIMAB DATA FOR ORAL PRESENTATION AT ESMO 2025 09 jul 2025 08:00

Faron Pharmaceuticals

Faron announces acceptance of two studies involving bexmarilimab, one of them as an oral presentation, at the 19th International Congress of Immunology (IUIS) 2025 02 jul 2025 12:00

Faron Pharmaceuticals

Faron Pharmaceuticals Ltd: Director Dealing 30 jun 2025 13:00

Faron Pharmaceuticals

Faron Pharmaceuticals Ltd: Director/PCA Dealing 30 jun 2025 08:00

Faron Pharmaceuticals

Faron-supported research in Theranostics identifies secreted Clever-1 (sClever-1) as an independent driver of immune evasion in cancer, deepening the understanding of bexmarilimab’s mode of action 12 jun 2025 08:00

Faron Pharmaceuticals

Faron Pharmaceuticals presents updated Phase II data from BEXMAB Study at EHA 2025 05 jun 2025 17:00

Faron Pharmaceuticals

Faron Pharmaceuticals Ltd: Director/PCA Dealing and Donation of Shares to Foundation 03 jun 2025 13:00

Faron Pharmaceuticals

Faron Pharmaceuticals Ltd: Registration of New Shares 03 jun 2025 08:00

Faron Pharmaceuticals

Faron Pharmaceuticals Ltd: Approval of Share Subscriptions Based on Special Rights in connection with Amortisation of the First Tranche Bonds 02 jun 2025 08:00

Faron Pharmaceuticals

Faron Pharmaceuticals presents Phase II data from BEXMAB Study at ASCO 2025 30 maj 2025 08:00

Faron Pharmaceuticals

Faron announces publication of full Phase I BEXMAB study data in Lancet Haematology 27 maj 2025 18:00

Faron Pharmaceuticals

Faron Pharmaceuticals Ltd: Issue of Treasury Shares to the Company 27 maj 2025 08:00

Faron Pharmaceuticals

Faron’s Bexmarilimab demonstrates immune-activating and drug-sensitizing potential in myeloid malignancies 23 maj 2025 08:00

Faron Pharmaceuticals

Faron announces new data that highlight patient populations with cancer that are most likely to benefit from first-in-class immunotherapy bexmarilimab 21 maj 2025 08:00

Faron Pharmaceuticals

Faron Appoints Ralph Hughes as Chief Business Officer (CBO)15 maj 2025 08:00

Faron Pharmaceuticals

Faron Announces Acceptance of Bexmarilimab Data for Oral Presentation at EHA 2025 Congress 14 maj 2025 15:00

Faron Pharmaceuticals

Faron Pharmaceuticals Ltd: Grant of Options 12 maj 2025 08:00

Faron Pharmaceuticals

Faron Pharmaceuticals presents promising Phase 1/2 data from BEXMAB Study at MDS 2025 plenary session 24 apr 2025 08:00

Faron Pharmaceuticals

Faron announces acceptance of bexmarilimab Phase II data for oral presentation at ASCO 2025 17 apr 2025 14:15

Faron Pharmaceuticals

Holding in Company 15 apr 2025 08:10

Faron Pharmaceuticals

Sisäpiiritieto: Faron julkistaa positiivisia II vaiheen tuloksia hoitoresistentin korkeariskin myelodysplastisen syndrooman hoidossa 15 apr 2025 08:00

Faron Pharmaceuticals

Inside Information: Faron Announces Positive Phase II results in higher-risk myelodysplastic syndrome 03 apr 2025 08:00

Faron Pharmaceuticals

Inside Information: Faron enters into an up to EUR 35 million convertible bond arrangement and issues first tranche of bonds with a principal amount of EUR 15 million 27 mar 2025 08:00

Faron Pharmaceuticals

Faron Announces Acceptance of Bexmarilimab Data for Oral Presentation at 2025 Annual MDS Foundation Congress 21 mar 2025 14:15

Faron Pharmaceuticals

Board Changes 21 mar 2025 12:45

Faron Pharmaceuticals

Results of the Annual General Meeting, Change of Directors, Decision of the Board meeting after the AGM 20 mar 2025 08:00

Faron Pharmaceuticals

Shareholders’ Nomination Board updates its recommendation on the number of Board members to be elected and the persons proposed to be elected 03 mar 2025 13:00

Faron Pharmaceuticals

Inside Information: FDA Grants Orphan Drug Designation for Bexmarilimab in MDS 28 feb 2025 13:00

Faron Pharmaceuticals

NOTICE OF FARON PHARMACEUTICALS LTD’S ANNUAL GENERAL MEETING 27 feb 2025 08:30

Faron Pharmaceuticals

Inside Information: Faron Receives Positive EMA Opinion on Orphan Drug Designation for Bexmarilimab for the treatment of myelodysplastic syndrome (MDS)27 feb 2025 08:15

Faron Pharmaceuticals

Faron Pharmaceuticals Ltd’s Annual Report 2024 published 27 feb 2025 08:00

Faron Pharmaceuticals

Faron’s Financial Statement Release 1 January to 31 December 2024 19 feb 2025 11:00

Faron Pharmaceuticals

Faron Pharmaceuticals will publish its Financial Statement Release 2024 and Annual Report 2024 on Thursday 27 February 2025 14 feb 2025 13:00

Faron Pharmaceuticals

Holding(s) in Company 11 feb 2025 08:30

Faron Pharmaceuticals

Change of Broker 06 feb 2025 16:00

Faron Pharmaceuticals

Holding(s) in Company 06 feb 2025 08:00

Faron Pharmaceuticals

Results of the Significantly Oversubscribed Placing 05 feb 2025 17:30

Faron Pharmaceuticals

Proposed Issue and Placing 31 jan 2025 08:00

Faron Pharmaceuticals

Final Patient Identified for the BEXMAB Study 16 maj 2024 16:01

Faron Pharmaceuticals

Faron Founders and bexmarilimab Developers Selected as Finalists for the European Inventor Award 2024 16 apr 2024 08:00

Faron Pharmaceuticals

Faron Confirms Plans for the Coming Months Under New Leadership 18 mar 2024 14:00

Faron Pharmaceuticals

Inside Information: Additional Positive Data from the Phase 1 Part of the BEXMAB Study in Both Higher-Risk HMA-Failed MDS and r/r AML 14 mar 2024 08:00

Faron Pharmaceuticals

Faron to Host Webcast to Discuss latest data from Phase 1 part of the BEXMAB Study of Bexmarilimab 13 mar 2024 08:00

Faron Pharmaceuticals

Faron’s Financial Statement Release January 1 to December 31, 2023 25 jan 2024 08:00

Faron Pharmaceuticals

Detailed Analysis of BEXMAB Data Provides Insights into Patient Profiles of Responding HMA-Failed MDS Population 03 jan 2024 08:00

Faron Pharmaceuticals

Faron Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference 11 dec 2023 08:00

Faron Pharmaceuticals

Inside information: Faron Presents Phase 1 Data from BEXMAB in Myeloid Malignancies Trial at the 65th American Society of Hematology (ASH) Annual Meeting 07 dec 2023 08:00

Faron Pharmaceuticals

Faron Announces Publication of Full Analysis from Phase 1/2 MATINS Trial of Bexmarilimab in Solid Tumors in Cell Reports Medicine 06 nov 2023 08:00

Faron Pharmaceuticals

Insider information: Faron Initiates Phase 2 Part of BEXMAB Study of Bexmarilimab in HMA-failed MDS 27 okt 2023 08:05

Faron Pharmaceuticals

Inside Information: Announcement of the Results of Placing, the Issue Price and registration of Placing Shares with the Trade Register 11 okt 2023 13:00

Faron Pharmaceuticals

Inside information: Faron Announces Positive BEXMAB Study Update in Relapsed/Refractory AML and HMA-Refractory MDS Patients 03 okt 2023 08:00

Faron Pharmaceuticals

Faron to Host Webcast to Discuss New Data From Phase I/II BEXMAB Study of Bexmarilimab and Provide Update on the Development Outlook for Next 6-9 Months 22 sep 2023 17:00

Faron Pharmaceuticals

Faron Pharmaceuticals Announces Board Changes